Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2a Study of Double-Immune Suppression Blockade By Combining a CSF1R Inhibitor (PLX3397) With An Anti-PD-1 Antibody (Pembrolizumab) To Treat Advanced Melanoma And Other Solid Tumors

NCT02452424 is registered in ClinicalTrials.gov with Daiichi Sankyo as lead sponsor.

NCT NCT02452424
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02452424 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2a Study of Double-Immune Suppression Blockade By Combining a CSF1R Inhibitor (PLX3397) With An Anti-PD-1 Antibody (Pembrolizumab) To Treat Advanced Melanoma And Other Solid Tumors
Lead sponsor
Daiichi Sankyo
Phase
Phase 1/2
Overall status
Terminated
Start date
July 2, 2015
Completion date
October 12, 2018
Enrollment
78 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

gastrointestinal stromal tumor (gist), melanoma, non-small cell lung cancer, ovarian cancer, squamous cell carcinoma of the head and neck